Xpert MTB/RIF (Cepheid) is a rapid molecular assay shown to be sensitive and specific for pulmonary tuberculosis (TB) diagnosis in highly endemic countries. We evaluated its diagnostic performance in a low TB prevalence setting, examined rifampicin resistance detection and quantitative capabilities predicting graded auramine microscopy and time to positivity (TTP) of culture.
Introduction
Diagnosing tuberculosis (TB) can be problematic as patients may present with a wide range of symptoms which may not be specific. In addition, the sensitivity of microscopy and smear positivity in respiratory TB ranges from 57-81%, potentially leading to misdiagnosis. 1 TB culture is the gold standard for diagnosing TB and allows drug susceptibilities to be tested.
There have been developments in rapid automated mycobacterial liquid culture systems and time to detection of growth of mycobacterial species can be shortened significantly. 2 Even with these advances there could be delays in diagnosis, leading to later initiation of appropriate therapy and implementation of infection prevention and control measures.
Xpert MTB/RIF (Cepheid) is a rapid, direct molecular test for the diagnosis of pulmonary TB and detection of rifampicin (RIF) resistance, which is a marker of multidrug resistant TB (MDRTB). 3 It has been endorsed by the World Health Organisation (WHO) and extensive evaluation has found it to be sensitive and specific for pulmonary TB diagnosis and detection of RIF resistance in high endemic countries for suspected cases of MDRTB. 4 Xpert MTB/RIF has lower sensitivity in HIV-associated TB. 5 There is however, considerably less data on the use of Xpert MTB/RIF in low prevalence countries despite increased use. 6 Recently a study to examine the use of Xpert MTB/RIF versus AFB smear and culture to identify pulmonary TB found that the diagnostic performance of Xpert MTB/RIF in the United States was similar to higher TB prevalence sites in Brazil and South Africa. 7 Scotland's TB incidence was 6.5 cases per 100,000 population in 2014 with low rates of MDR-TB (around 0.9%). 8 In that year, Scotland had an estimated rate of 1. excluded. 10 The Public Health England (PHE) position statement published in July 2013 states that molecular testing of M. tuberculosis complex (MTBC) on respiratory samples is superior to smear microscopy for the diagnosis of TB and should be accessible in all areas of Scotland, England and Wales with results available within 1 -2 working days of the sample being taken. 11 The objective of this study was to evaluate the performance of Xpert MTB/RIF for detection of pulmonary TB in patients from the Tayside region of Scotland which has a low TB and HIV prevalence. In addition we aimed to examine the quantitative capabilities of Xpert MTB/RIF in relation to predicting auramine stain grading, as well as looking at TTP of culture. 
Materials and Methods

Study Design and clinical samples
Sample processing
Respiratory samples were sent to SMRL where they were liquefied and concentrated using Sputasol (1:1 v/v; Oxoid) and a loopful of sediment used to prepare a smear for auramine phenol microscopy using standard laboratory methods. 12 The number of AFB present was scored as: + (few AFB, one to 10 bacilli in 10 fields), ++ (moderate AFB, one to 10 bacilli per field) or +++ (many AFB, 10 or more bacilli per field). Specimen decontamination was performed with 2% NaOH-NALC and the pellet resuspended in 1.5ml phosphate buffer. 0.5ml was used to inoculate both a LJ with pyruvate slope and a BACTEC MGIT 960 tube (Becton Dickinson) and 0.5ml was stored at -20 o C for further additional molecular testing where appropriate.
Culture identification
Cultured mycobacteria were identified using GenoType® MTBC GenoType® Mycobacteria CM v1.0 or GenoType® Mycobacteria AS v1.0 (HAIN Lifescience) following the manufacturer's instructions. 13, 14 MGIT and LJ cultures were considered to have a negative result if no mycobacterial growth was seen after 6 or 12 weeks of incubation respectively.
All MTBC-positive specimens were tested for resistance to RIF and INH using GenoType® MTBDRplus v1.0 and v2.0 (HAIN Lifescience) to confirm the Xpert RIF-resistance result and confirmed by phenotypic methods. 15, 16 
Statistical analysis
Clinical and laboratory data were stored in Microsoft Excel analysed using simple descriptive methods in IBM SPSS version 23. Consecutive samples from the same patient were included in our analysis. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Xpert MTB/RIF were calculated with 95% confidence intervals (CI). 17 Chi-squared test for trend was used to compare proportions across ordered categories.
A Kruskal-Wallis test was used to compare the distributions of times to positivity between subgroups.
Ethics Approval
Caldicott guardian approval was gained from NHS Tayside in order to enable appropriate information sharing and protect the confidentiality of patients.
Results
Performance of Xpert MTB/RIF
A total of 2103 Xpert MTB/RIF tests were performed on samples from 1299 patients ( Figure   1 ). . They responded to standard antibiotic treatment for pneumonia and following review in the infectious disease clinic after admission it was decided there was no good evidence the patient had TB. It appears therefore that this patient had a true false-positive Xpert MTB/RIF result.
For the 51 ETA and 5 induced sputum all cultures were MTBC negative. The sensitivity, specificity, NPV, PPV and 95% confidence interval (CI) of Xpert MTB/RIF for sputum and BAL samples is shown in Table 2 .Within those with a culture result available, the PPV increased with the increasing category of the Xpert MTB/RIF assay load results. 
Detection of Rifampicin Resistance
One patient in the study was diagnosed with multi-drug resistant (MDR) TB using direct GenoType MTBDRplus at SMRL. Although two wild-type rpoB bands were not detected, no mutation was identified using this assay suggesting that another rpoB mutation was present to 
Xpert MTB/RIF and Microscopy
Overall there were 1927 samples in which microscopy was carried out. It can be seen in Table 3 and Figure 2 that there is a clear positive relationship between AFB microscopy grade and the Xpert MTB/RIF assay load results even when 97 atypical mycobacteria are included. Of these there were 57 non-tuberculous mycobacteria (NTM) with no AFB seen on microscopy, 20 with few AFB seen on microscopy, and 20 with moderate AFB seen on microscopy. The percentages in the upper two microscopy groups increased as the Xpert MTB/RIF assay load results increased, from 0%, 0% and 47.0%, to 84.6%. A chi-squared test for trend confirmed the statistical significance of these findings (p<0.001). 
Xpert MTB/RIF and TTP
We examined time to positivity (TTP) in the 48 culture positive samples (Table 4 ). This ranged from 6 to 56 days and was highly positively skewed. The median TTP was 10 days.
There was a clear reduction in the median TTP as the Xpert MTB/RIF assay load results increased. A Kruskal-Wallis test comparing times to positivity in the Cepheid PCR categories showed a significant difference with p=0.005. In this study, the Xpert MTB/RIF had a sensitivity and specificity of 95.3% and 99.3%
respectively when used on sputum samples. These figures are similar to previously reported studies in high prevelence areas. 6 The sensitivity of Xpert MTB/RIF on BAL specimens was M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 15 found to be 100.0% which is higher in comparison to the findings of a previous study where is was found to be 81.6%. 18 A recent study involving the Xpert MTB/RIF in Canada found it had a sensitivity of 46% and specificity of 100% for detection of MTB from induced sputum samples. The authors concluded that paucibacillary disease and dilution of the sample in the process of sputum induction may have accounted for its low sensitivity. 19 There were small numbers of ETA and induced sputum submitted all of which were culture-negative. In particular the 5 induced sputa were sampled from 5 different patients. This could be said to have been observed as having 100% specificity but we cannot say if this would be true using a larger number of samples
The percentage of samples which were invalid using Xpert MTB/RIF was 1.8% (a total of 38 samples). Invalid results indicate that the sample processing control (SPC) has failed because the sample was either not properly processed or PCR was inhibited. In real life comparisons of methods there may be invalid results which can affect the usefulness of tests. Our rate of invalids was lower than previously reported. 19 It has previously been described that the Xpert MTB/RIF is not specific for the detection of rifampicin resistance as silent mutations in the rpoB gene can give rise to the detection of false-positive rifampicin resistance. 20 We cannot comment on whether false positive readings can arise from silent mutations as we only found one patient who had MDRTB. Xpert MTB/RIF detected rifampicin resistance in 9/9 samples and this was confirmed by the reference laboratory's standard methods. Another limitation of this study is that we cannot provide the HIV status of the Xpert MTB/RIF tested patients.
We found a clear positive relationship between AFB microscopy grade and the Xpert MTB/RIF assay load results and this was statistically significant (p<0.001). Additionally, a clear reduction in the median TTP as the Xpert MTB/RIF assay load results increased was found. A Kruskal-Wallis test comparing distributions of times to positivity in the Xpert MTB/RIF categories showed a significant difference (p=0.005). These results support similar findings from previous studies. 21 
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Highlights
• Xpert MTB/RIF gave accurate results in a low TB and HIV prevalence setting
• It had a very good NPV useful for ruling out pulmonary TB
• Auramine microscopy grade and Xpert MTB/RIF assay load correlated
• Median TTP reduced as Xpert MTB/RIF assay load increased
• Molecular testing respiratory samples may be appropriate for infectivity assessment
